# US 2023/0053411 A1 · 1,3-thiazol-2-yl substituted benzamides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053411 A1
- Document ID: US20230053411A1
- Status: Published application
- Kind: A1
- Application number: 17/470,459
- Filed: 2021-09-09
- Published: 2023-02-23
- Earliest claimed: 2014-12-09
- Assignees: Bayer Aktiengesellschaft
- Applicants: Bayer Aktiengesellschaft
- Inventors: Adam James DAVENPORT; Nico BRÄUER; Oliver Martin FISCHER; Andrea ROTGERI; Antje ROTTMANN; Ioana NEAGOE; Jens NAGEL; Anne-Marie GODINHO-COELHO; Jürgen KLAR
- Web page: https://patentgrep.com/patent/US20230053411A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- C07D 417/14: containing three or more hetero rings
- C07D 471/08: Bridged systems
- C07D 498/08: Bridged systems
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

## Claims

### Claim at position 1

1: A compound of general formula (I):
in which
R1 represents a halogen atom, C1-C4-alkyl or C3-C6-cycloalkyl, wherein C1-C4-alkyl is optionally substituted with 1-5 halogen atoms which are the same or different;
R2 represents —C2-C6-alkyl-OR4, —(CH2)q-(C3-C7-cycloalkyl), —(CH2)q-(6- to 12-membered heterobicycloalkyl), —(CH2)q-(4- to 7-membered heterocycloalkyl), —(CH2)q-(5- to 10-membered heteroaryl) or —C2-C6-alkynyl; and
wherein said —(CH2)q-(C3-C7-cycloalkyl), —(CH2)q-(6- to 12-membered heterobicycloalkyl) and —(CH2)q-(4- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents which are the same or different, at any ring carbon atom and selected from the group consisting of C1-C4 alkyl, optionally substituted with 1-5 halogen atoms which are the same or different, a halogen atom, —NRaRb, COOR5 and oxo (═O); and
wherein independently any ring nitrogen atom, if present in said —(CH2)q-(6- to 12-membered heterobicycloalkyl) and —(CH2)q-(4- to 7-membered heterocycloalkyl) is substituted with Rc; and
wherein said —(CH2)q-(5- to 10-membered heteroaryl) is optionally substituted with one or more substituents which are the same or different, and selected from the group consisting of C1-C4-alkyl, optionally substituted with 1-5 halogen atoms which are the same or different, a halogen atom, —NRaRb and —COOR5;
R3 represents hydrogen or C1-C4-alkyl, which is optionally substituted with 1-5 halogen atoms which are the same or different;
R4 and R5 represent hydrogen or C1-C4-alkyl;
Ra and Rb represent hydrogen or C1-C4-alkyl;
Rc represents hydrogen, C1-C4-alkyl, optionally substituted with 1-5 halogen atoms which are the same or different, —C(O)O—C1-C4-alkyl, or —C(O)—C1-C4-alkyl;
A represents 5- to 10-membered heteroaryl which is optionally substituted with one or more substituents, which are the same or different, and selected from the group consisting of a halogen atom, C1-C3-alkyl, and C1-C3-alkoxy, wherein C1-C3-alkyl and C1-C3-alkoxy are optionally substituted with 1-5 halogen atoms which are the same or different;
q represents an integer of 0, 1, or 2;
or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or a salt thereof, or a mixture of same.

### Claim at position 2 (depends on 1)

2: A compound according to claim 1 having general formula (Ia):
in which A, R1, R2 and R3 have the meanings as defined in claim 1, and R3 preferably represents C1-C4-alkyl, more preferably methyl.

### Claim at position 3 (depends on 1)

3: A compound according to claim 1, wherein
A represents an optionally substituted 5- or 6-membered heteroaryl, preferably an optionally substituted 6-membered heteroaryl.

### Claim at position 4 (depends on 1)

4: A compound according to claim 1, wherein
R1 represents C1-C4-alkyl, preferably methyl or ethyl.

### Claim at position 5 (depends on 1)

5: A compound according to claim 1, wherein
R3 represents C1-C4-alkyl, preferably methyl.

### Claim at position 6 (depends on 1)

6: A compound according to claim 1, wherein
R2 represents —C2-C3-alkyl-OR4, —CH2-(C3-C4-cycloalkyl), C3-C4-cycloalkyl, —(CH2)q-(4- to 6-membered heterocycloalkyl), or —C2-C4-alkynyl; and
wherein said —CH2-(C3-C4-cycloalkyl), C3-C4-cycloalkyl and —(CH2)q-(4- to 6-membered heterocycloalkyl) are optionally substituted with one or more substituents which are the same or different, at any ring carbon atom; and
wherein independently any ring nitrogen atom, if present in said —(CH2)q-(4- to 6-membered heterocycloalkyl) is substituted with Rc; and
q represents an integer of 0.

### Claim at position 7 (depends on 1)

7: A compound according to claim 1, wherein
A represents an optionally substituted 5- or 6-membered heteroaryl, preferably an optionally substituted 6-membered heteroaryl; and
R1 represents C1-C4-alkyl, preferably methyl or ethyl.

### Claim at position 8 (depends on 1)

8: A compound according to claim 1, wherein
A represents an optionally substituted 5- or 6-membered heteroaryl, preferably an optionally substituted 6-membered heteroaryl; and
R3 represents C1-C4-alkyl, preferably methyl.

### Claim at position 9 (depends on 1)

9: A compound according to claim 1, wherein
A represents an optionally substituted 5- or 6-membered heteroaryl, preferably an optionally substituted 6-membered heteroaryl;
R1 represents C1-C4-alkyl, preferably methyl or ethyl; and
R3 represents C1-C4-alkyl, preferably methyl.

### Claim at position 10 (depends on 1)

10: A compound according to claim 1, wherein
A represents an optionally substituted 5- or 6-membered heteroaryl, preferably an optionally substituted 6-membered heteroaryl;
R1 represents C1-C4-alkyl, preferably methyl or ethyl;
R2 represents —C2-C3-alkyl-OR4, —CH2-(C3-C4-cycloalkyl), C3-C4-cycloalkyl, —(CH2)q-(4- to 6-membered heterocycloalkyl), or —C2-C4-alkynyl; and
wherein said —CH2-(C3-C4-cycloalkyl), C3-C4-cycloalkyl and —(CH2)q-(4- to 6-membered heterocycloalkyl) are optionally substituted with one or more substituents which are the same or different, at any ring carbon atom; and
wherein independently any ring nitrogen atom, if present in said —(CH2)q-(4- to 6-membered heterocycloalkyl) is substituted with Rc;
R3 represents C1-C4-alkyl, preferably methyl; and
q represents an integer of 0.

### Claim at position 11 (depends on 1)

11: A compound according to claim 1, wherein
A represents 5- or 6-membered heteroaryl at least containing one or two nitrogen atom(s), preferably a 6-membered heteroaryl with one or two nitrogen atom(s),
wherein said 5- or 6-membered heteroaryl is optionally substituted one or two times, identically or differently, with a substituent selected from a fluorine or chlorine atom, C1-C2-alkyl, optionally substituted with 1-5 fluorine atoms, or C1-C2-alkoxy, optionally substituted with 1-5 fluorine atoms;
R1 represents methyl or ethyl;
R2 represents —C2-C3-alkyl-OR4, unsubstituted —CH2-(C3-C4-cycloalkyl), unsubstituted C3-C4-cycloalkyl, unsubstituted (CH2)q-(4- to 6-membered heterocycloalkyl), or —C2-C4-alkynyl;
q represents an integer of 0; and
R3 represents methyl.

### Claim at position 12 (depends on 1)

12: A compound according to claim 1, wherein A represents pyrimidinyl, pyridazinyl, pyridinyl, pyrazinyl, thiazolyl or thiadiazolyl, preferably pyrimidinyl, pyridazinyl, thiazolyl or thiadiazolyl, more preferably pyrimidinyl, pyridazinyl or thiadiazolyl, wherein said pyrimidinyl, pyridazinyl, pyridinyl, pyrazinyl, thiazolyl and thiadiazolyl are optionally substituted.

### Claim at position 13 (depends on 1)

13: A compound according to claim 1, wherein A represents CF3-pyrimidinyl, preferably 2-CF3-pyrimidin-5-yl.

### Claim at position 14 (depends on 1)

14: A compound according to claim 1, wherein R2 represents cyclopropylmethyl, tetrahydrofuran-3-yl, tetrahydrofuran-2-ylmethyl, tetrahydrofuran-3-ylmethyl, prop-2-yn-1-yl, but-2-yn-1-yl, oxetan-3-yl, tetrahydropyran-4-yl, tetrahydro-2H-pyran-4-ylmethyl, pyridin-4-yl, pyridin-3-yl, 1,3,4-thiadiazol-2-yl, 1,3-thiazol-2-yl, 2,2-dimethyl-2-methoxyethyl, methoxyethyl, piperidin-4-yl, pyrrolidin-3-yl or azetidin-3-yl which are optionally substituted, preferably unsubstituted cyclopropylmethyl, unsubstituted oxetan-3-yl or unsubstituted tetrahydrofuran-3-yl.

### Claim at position 15 (depends on 1)

15: A compound according to claim 1, wherein R2 represents unsubstituted tetrahydrofuran-3-yl or unsubstituted oxetan-3-yl.

### Claim at position 16 (depends on 1)

16: A compound according to claim 1, wherein
R2 represents —(CH2)q-(4- to 6-membered heterocycloalkyl); and wherein (CH2)q-(4- to 6-membered heterocycloalkyl) is optionally substituted with one or more substituents which are the same or different, at any ring carbon atom; and
wherein independently any ring nitrogen atom, if present in said —(CH2)q-(4- to 6-membered heterocycloalkyl) is substituted with Rc; and wherein —(CH2)q-(4- to 6-membered heterocycloalkyl) is preferably
—(CH2)q-morpholinyl; and
q represents an integer of 1.

### Claim at position 17 (depends on 16)

17: A compound according to claim 16, wherein R2 represents —(CH2)q-morpholinyl substituted with Rc, and wherein Rc preferably represents methyl.

### Claim at position 18 (depends on 17)

18: A compound according to claim 17, wherein
R2 represents (4-methylmorpholin-2-yl)methyl, preferably [(2R)-4-methylmorpholin-2-yl]methyl or [(2S)-4-methylmorpholin-2-yl]methyl, more preferably [(2R)-4-methyl-morpholin-2-yl]methyl.

### Claim at position 19 (depends on 1)

19: A compound according to claim 1, wherein
R2 represents —C2-C4-alkyl-OH and
R1 represents halogen, preferably chloro.

### Claim at position 20 (depends on 1)

20: A compound according to claim 1, wherein
R2 represents 3-hydroxybutan-2-yl, preferably (2R,3R)-3-hydroxybutan-2-yl, (2S,3S)-3-hydroxybutan-2-yl, (2S,3R)-3-hydroxybutan-2-yl or (2R,3 S)-3-hydroxybutan-2-yl, more preferably (2R,3R)-3-hydroxybutan-2-yl or (2S,3S)-3-hydroxybutan-2-yl.

### Claim at position 21 (depends on 1)

21: A compound according to claim 1, wherein
A represents an optionally substituted pyrimidinyl or pyridazinyl, wherein said pyrimidinyl or pyridazinyl are optionally substituted with one or two substituents which are the same or different, and selected from a fluorine or chlorine atom, C1-C2-alkyl, optionally substituted with 1 to 5 fluorine atoms, or C1-C2-alkoxy, optionally substituted with 1 to 5 fluorine atoms; preferably CF3-pyrimidinyl or 6-CF3-pyridazinyl, more preferably 2-CF3-pyrimidin-5-yl or 6-CF3-pyridazin-3-yl.

### Claim at position 22 (depends on 1)

22: A compound according to claim 1, namely
3-(5-Methyl-1,3-thiazol-2-yl)-5-[(3R)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-Methyl-1,3-thiazol-2-yl)-5-[(3S)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-Methyl-1,3-thiazol-2-yl)-5-(oxetan-3-yloxy)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-Ethyl-1,3-thiazol-2-yl)-5-[(3R)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-Ethyl-1,3-thiazol-2-yl)-5-[(3S)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-Ethyl-1,3-thiazol-2-yl)-5-(oxetan-3-yloxy)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-Methyl-1,3-thiazol-2-yl)-5-[(3R)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl}benzamide;
3-(5-Methyl-1,3-thiazol-2-yl)-5-[(3S)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl}benzamide.

### Claim at position 23 (depends on 1)

23: A compound according to claim 1, namely
3-(5-methyl-1,3-thiazol-2-yl)-5-[(3R)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-methyl-1,3-thiazol-2-yl)-5-[(3S)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide.

### Claim at position 24 (depends on 23)

24: A compound according to claim 23, namely 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3R)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide.

### Claim at position 25 (depends on 1)

25: A compound according to claim 1, namely
3-(5-ethyl-1,3-thiazol-2-yl)-5-{[(2R)-4-methylmorpholin-2-yl]methoxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-{[(2R)-4-methylmorpholin-2-yl]methoxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
3-(5-ethyl-1,3-thiazol-2-yl)-5-{[(2R)-4-methylmorpholin-2-yl]methoxy}-N-{(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl}benzamide.

### Claim at position 26 (depends on 25)

26: A compound according to claim 25, namely 3-{[(2R)-4-methylmorpholin-2-yl]methoxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide.

### Claim at position 27 (depends on 1)

27: A compound according to claim 1, namely
Trans Isomer 2; 3-{[3-hydroxybutan-2-yl]oxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
Trans Isomer 1; 3-{[3-hydroxybutan-2-yl]oxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl}benzamide;
Trans Isomer 1; 3-(5-chloro-1,3-thiazol-2-yl)-5-{[3-hydroxybutan-2-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
Cis Isomer 1; 3-(5-chloro-1,3-thiazol-2-yl)-5-{[3-hydroxybutan-2-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
Cis Isomer 2; 3-(5-chloro-1,3-thiazol-2-yl)-5-{[3-hydroxybutan-2-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
Trans Isomer 2; 3-(5-chloro-1,3-thiazol-2-yl)-5-{[3-hydroxybutan-2-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
Cis Isomer 1; 3-[(-3-hydroxybutan-2-yl)oxy]-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl}benzamide;
Cis Isomer 2; 3-[(-3-hydroxybutan-2-yl)oxy]-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl}benzamide;
Cis Isomer 1; 3-[(3-hydroxybutan-2-yl)oxy]-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
Cis Isomer 2; 3-[(3-hydroxybutan-2-yl)oxy]-5-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide.

### Claim at position 28 (depends on 27)

28: A compound according to claim 27, namely Cis Isomer 1; 3-(5-chloro-1,3-thiazol-2-yl)-5-{[3-hydroxybutan-2-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide.

### Claim at position 29 (depends on 1)

29: A pharmaceutical composition comprising a compound according to claim 1, or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, and a pharmaceutically acceptable diluent or carrier.

### Claim at position 30 (depends on 1)

30: Use of a compound according to claim 1, or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of a disease.

### Claim at position 31 (depends on 1)

31: Use of a compound according to claim 1, or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the preparation of a medicament for the prophylaxis or treatment of a disease.

### Claim at position 32 (depends on 30)

32: Use according to claim 30, wherein said disease is a genitourinary, gastrointestinal, respiratory or pain-related disease, condition or disorder; gynecological diseases including dysmenorrhea, dyspareunia, and endometriosis; endometriosis-associated pain; endometriosis-associated symptoms, wherein said symptoms are in particular dysmenorrhea, dyspareunia, dysuria, or dyschezia; urinary tract disease states associated with the bladder outlet obstruction; urinary incontinence conditions such as reduced bladder capacity, increased frequency of micturition, urge incontinence, stress incontinence, or bladder hyperreactivity; benign prostatic hypertrophy; prostatic hyperplasia; prostatitis; detrusor hyperreflexia; overactive bladder and symptoms related to overactive bladder wherein said symptoms are in particular increased urinary frequency, nocturia, urinary urgency or urge incontinence; pelvic hypersensitivity; urethritis; prostatitis; prostatodynia; cystitis; idiopathic bladder hypersensitivity; epilepsy; partial and generalized seizures; respiratory disorders including chronic obstructive pulmonary disorder (COPD), asthma, bronchospasm, chronic cough and the like; gastrointestinal disorders including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, gastroesophageal reflux, gastrointestinal distension, Crohn's disease and the like; Parkinson's disease; Alzheimer's disease; myocardial infarction; lipid disorders; and pain-associated diseases selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome), arthritis (such as osteoarthritis and rheumatoid arthritis), burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer, traumatic nerve-injury, post-traumatic injuries (including fractures and sport injuries), trigeminal neuralgia, small fiber neuropathy, diabetic neuropathy, chronic arthritis and related neuralgias, HIV and HIV treatment-induced neuropathy, pruritus.

### Claim at position 33 (depends on 1)

33: Use according to claim 1, wherein said disease is a gynecological disease, preferably dysmenorrhea, dyspareunia or endometriosis, endometriosis-associated pain, or other endometriosis-associated symptoms, wherein said symptoms are in particular dysmenorrhea, dyspareunia, dysuria, or dyschezia.

### Claim at position 34 (depends on 1)

34: Use according to claim 1, wherein said disease is associated with pain syndromes (including acute, chronic, inflammatory and neuropathic pain), preferably inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, endometriosis-associated pain, central pain, pain due to burning mouth syndrome, pain due to burns, pain due to migraine, cluster headaches, pain due to nerve injury, pain due to neuritis, neuralgias, pain due to poisoning, pain due to ischemic injury, pain due to interstitial cystitis, cancer pain, pain due to viral, parasitic or bacterial infections, pain due to traumatic nerve-injury, pain due to post-traumatic injuries (including fractures and sport injuries), pain due to trigeminal neuralgia, pain associated with small fiber neuropathy, pain associated with diabetic neuropathy, chronic lower back pain, phantom limb pain, pelvic pain syndrome, chronic pelvic pain, neuroma pain, complex regional pain syndrome, pain associated with gastrointestinal distension, chronic arthritic pain and related neuralgias, and pain associated with cancer, pain associated with chemotherapy, HIV and HIV treatment-induced neuropathy; and pain associated with diseases or disorders selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome) and arthritis (such as osteoarthritis and rheumatoid arthritis).

### Claim at position 35 (depends on 1)

35: A compound according to claim 1, or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the manufacture of a medicament.

### Claim at position 36 (depends on 1)

36: A compound according to claim 1, or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for use in the treatment of genitourinary, gastrointestinal, respiratory or pain-related disease, condition or disorder; gynecological diseases including dysmenorrhea, dyspareunia, and endometriosis; endometriosis-associated pain; endometriosis-associated symptoms, wherein said symptoms are in particular dysmenorrhea, dyspareunia, dysuria, or dyschezia; urinary tract disease states associated with the bladder outlet obstruction; urinary incontinence conditions such as reduced bladder capacity, increased frequency of micturition, urge incontinence, stress incontinence, or bladder hyperreactivity; benign prostatic hypertrophy; prostatic hyperplasia; prostatitis; detrusor hyperreflexia; overactive bladder and symptoms related to overactive bladder wherein said symptoms are in particular increased urinary frequency, nocturia, urinary urgency or urge incontinence; pelvic hypersensitivity; urethritis; prostatitis; prostatodynia; cystitis; idiopathic bladder hypersensitivity; epilepsy; partial and generalized seizures; respiratory disorders including chronic obstructive pulmonary disorder (COPD), asthma, bronchospasm, chronic cough and the like; gastrointestinal disorders including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, gastroesophageal reflux, gastrointestinal distension, Crohn's disease and the like; Parkinson's disease; Alzheimer's disease; myocardial infarction; lipid disorders; and pain-associated diseases selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome), arthritis (such as osteoarthritis and rheumatoid arthritis), burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, traumatic nerve-injury, post-traumatic injuries (including fractures and sport injuries), trigeminal neuralgia, small fiber neuropathy, diabetic neuropathy, chronic arthritis and related neuralgias, HIV and HIV treatment-induced neuropathy, pruritus.

### Claim at position 37 (depends on 1)

37: A compound according to claim 1, or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for use in the treatment of pain syndromes (including acute, chronic, inflammatory and neuropathic pain), preferably inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, endometriosis-associated pain, central pain, pain due to burning mouth syndrome, pain due to burns, pain due to migraine, cluster headaches, pain due to nerve injury, pain due to neuritis, neuralgias, pain due to poisoning, pain due to ischemic injury, pain due to interstitial cystitis, cancer pain, pain due to viral, parasitic or bacterial infections, pain due to traumatic nerve-injury, pain due to post-traumatic injuries (including fractures and sport injuries), pain due to trigeminal neuralgia, pain associated with small fiber neuropathy, pain associated with diabetic neuropathy, chronic lower back pain, phantom limb pain, pelvic pain syndrome, chronic pelvic pain, neuroma pain, complex regional pain syndrome, pain associated with gastrointestinal distension, chronic arthritic pain and related neuralgias, and pain associated with cancer, pain associated with chemotherapy, HIV and HIV treatment-induced neuropathy; and pain associated with diseases or disorders selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome) and arthritis (such as osteoarthritis and rheumatoid arthritis).

### Claim at position 38 (depends on 1)

38: A compound according to claim 1 or an isomer, enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for use in the treatment of a gynecological disease, preferably dysmenorrhea, dyspareunia or endometriosis, endometriosis-associated pain, or other endometriosis-associated symptoms, wherein said symptoms are in particular dysmenorrhea, dyspareunia, dysuria, or dyschezia.
